Central to this advancement is the reconsideration of the radiolabeling process, traditionally a painstaking and labor-intensive procedure that requires several hours of meticulous manual action to attach the radioactive lutetium-177 to a carrier molecule, known as a DOTA chelator, before combining it with the delicate targeting molecule. This conventional multi-step approach, involving elevated temperatures and cooling phases, often compromises the sensitive molecular architecture of the targeting agent due to its vulnerability to heat and acid conditions, presenting significant technical hurdles.

The research, spearheaded by Meltem Ocak and Carolyn Anderson at the University of Missouri’s Molecular Imaging and Theranostics Center, alongside CTT’s Bea Langton-Webster and ITG’s Jim Simón, introduces an ingenious single-step synthesis technique that simplifies and expedites this process. By chemically pre-linking the targeting molecule to the DOTA chelator, the team was able to radiolabel the compound by gently heating it to 60 degrees Celsius, an optimum temperature that preserves the structural integrity of the targeting moiety while allowing efficient chelation of lutetium-177.

This temperature-controlled reaction is seamlessly integrated into a commercially available automated synthesis unit housed at the University of Missouri Research Reactor (MURR), a facility renowned for its production of life-saving isotopes. The process thus reduces synthesis time from approximately six hours to a mere 38 minutes, dramatically enhancing production throughput and reproducibility. The automation not only curtails human exposure to radioactive materials, significantly improving operator safety, but also aligns with industry demands for scalable, standardized production methods requisite for extensive clinical trials.

Preclinical evaluations validated that this accelerated and automated radiolabeling method produces a radiopharmaceutical with efficacy comparable to that generated through traditional laborious techniques. This equivalency in therapeutic performance underscores the viability of the novel approach for ongoing and future clinical applications aimed at combatting advanced prostate cancer. The breakthrough presents a pivotal step toward realizing broader accessibility to targeted radiotherapies, which have been hitherto limited by complex manufacturing constraints.

Beyond the immediate application to CTT1403, this pioneering work sets a compelling precedent for the radiochemical synthesis of other targeted cancer therapeutics. The concept of developing pre-assembled chelator-targeting molecule conjugates amenable to lower-temperature and automated radiolabeling could be extrapolated to a spectrum of radiotherapeutics, expediting their bench-to-bedside translation.

Moreover, the portability of the synthesis apparatus heralds a vision where such systems could be deployed within clinical environments, such as hospitals and radiopharmacies, potentially enabling onsite production of personalized cancer treatments. This advancement promises to diminish logistical barriers and latency in drug delivery, ultimately enhancing patient access to innovative therapies in real time.

The University of Missouri’s confluence of expertise in isotopic production at MURR and radiopharmaceutical chemistry uniquely positions it as a fertile nexus for continued innovation in this domain. Carolyn Anderson, a distinguished professor and associate director at the Ellis Fischel Cancer Center, underscores the transformative impact of this work, highlighting the potential to replicate or adapt this radiolabeling protocol for diverse diagnostic and therapeutic agents using lutetium-177.

Recognition of this research includes accolades such as the Drs. Jane & Abass Alavi Mars Shot Research Award granted to Anderson, evidencing the scientific community’s appreciation for advancements in nuclear medicine and molecular imaging. The study appears in the prestigious journal Nuclear Medicine and Biology, providing a detailed blueprint of the automated one-step radiolabeling methodology, supported by funding from the National Cancer Institute.

As the oncology field increasingly gravitates toward precision medicine, methodologies that facilitate rapid, reliable, and safe synthesis of targeted radiotherapeutics will be indispensable. This research not only exemplifies such innovation but also accelerates the journey toward scalable clinical deployment of next-generation cancer treatments with enhanced efficacy and patient tolerability.

Subject of Research: People

Article Title: Development of an automated one-step radiolabeling procedure for a PSMA-targeted radiotherapeutic for prostate cancer

News Publication Date: 29-Jan-2026

Web References:
http://dx.doi.org/10.1016/j.nucmedbio.2026.109607

References:
National Cancer Institute (funder)

Image Credits:
University of Missouri

Keywords:
Biomedical engineering, Clinical medicine, Diseases and disorders, Health care, Human health, Medical specialties, Pharmaceuticals, Pharmacology, Health and medicine

Traditionally, radiotherapy for localized prostate cancer involves multiple sessions spread over several weeks, typically five doses, to precisely target cancerous tissue while sparing surrounding healthy organs. This standard approach prioritizes thorough treatment delivery but imposes significant logistical challenges for patients, requiring daily hospital visits that disrupt personal and professional life. The latest research challenges this paradigm by evaluating a radically condensed treatment schedule.

The HERMES study, spearheaded by Dr. Sian Cooper, a Clinical Research Fellow at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research in London, represents one of the pioneering randomized controlled trials directly comparing two-session radiotherapy to the standard five-session protocol. This trial is particularly notable for employing state-of-the-art MRI-guided radiotherapy technology, allowing unprecedented targeting precision.

MRI-guided radiotherapy machines integrate real-time magnetic resonance imaging with radiation delivery systems, enabling clinicians to visualize the prostate and surrounding tissues with exceptional clarity during treatment. This precision minimizes radiation exposure to non-targeted areas like the bladder and rectum, thereby potentially reducing common side effects such as urinary and bowel dysfunction. Utilizing this advanced technology was critical in ensuring the safety of the condensed two-dose regimen.

The study enrolled 46 patients with localized prostate cancer, randomly assigning 24 individuals to receive the conventional five-dose treatment over two weeks, and 22 individuals to the novel two-dose treatment administered across eight days. Both groups received equivalent total radiation doses, ensuring a fair comparison regarding treatment effectiveness and toxicity profiles.

Follow-up analysis indicated that patients undergoing the two-dose radiotherapy protocol experienced side effects comparable to their counterparts receiving the standard five-dose treatments. Approximately 25% of patients in both cohorts reported moderate urinary symptoms like increased frequency or urgency between six months and two years post-treatment. Importantly, severe urinary or bowel side effects were absent, and no bowel side effects were reported in the two-session treatment group.

Patient-reported outcomes further demonstrated minimal changes in quality of life metrics after two years of follow-up, confirming that the condensed treatment did not compromise patient well-being. These findings suggest that the delivery of higher radiation doses in fewer sessions using MRI-guided radiotherapy is not only feasible but also clinically justified without elevating patient risks.

Establishing the safety profile of the two-session protocol carries profound implications for both patients and healthcare systems. For patients, reducing treatment duration from weeks to days alleviates the substantial inconvenience and psychological stress of frequent hospital visits, especially benefiting those residing far from specialized radiotherapy centers. This enhancement in convenience can improve treatment adherence and overall patient satisfaction.

For healthcare providers and hospitals, the adoption of shorter radiotherapy courses translates to increased throughput and resource efficiency. Fewer sessions per patient free up machine time and clinical staff capacity, allowing more patients to be treated and potentially reducing healthcare costs. Such operational advantages are vital in managing the increasing global demand for cancer treatments.

Professor Matthias Guckenberger, ESTRO President and radiation oncology expert at University Hospital Zurich, underscored the transformative potential of the study. He highlighted that radiotherapy remains among the most effective prostate cancer treatments due to its non-invasive nature and preservation of critical functions. This new research challenges longstanding conventions by demonstrating that a condensed regimen retains therapeutic benefits while maintaining low toxicity.

Despite the promising results, the availability of MRI-guided radiotherapy technology remains limited to specialized centers worldwide. However, the rapid expansion of these sophisticated machines suggests that broader implementation of two-dose radiotherapy protocols could soon become feasible. Ongoing and future trials will be essential to further validate these findings and facilitate the integration of this approach into standard clinical practice.

In conclusion, the HERMES study represents a milestone in oncological treatment innovation, offering a safer, faster, and potentially more accessible radiotherapy alternative for prostate cancer patients. Through harnessing advanced imaging and radiation delivery technologies, clinicians are poised to redefine care paradigms, improving patient experiences and outcomes without compromising treatment quality.

Subject of Research: People
Article Title: Not specified
News Publication Date: Not specified
Web References: Not specified
References: Not specified
Image Credits: Not specified

Keywords: Cancer, Radiation therapy, Prostate cancer, Side effects